Ravi Rajaram

Prof. Ravi Rajaram

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2023 in Chest
Verified
Journal Article
Open access
RRRavi Rajaram
Ravi Rajaram
QHQing Huang
Qing Huang
RLRichard Z. Li
Richard Z. Li
UCUrmila Chandran
Urmila Chandran
YZYuxin Zhang
Yuxin Zhang
IKIftekhar Kalsekar
Iftekhar Kalsekar
Standard treatment for early-stage or locoregionally-advanced non-small cell lung cancer (NSCLC) includes surgical resection. Recurrence after surgery is commonly reported, but a summary estimate for post-surgical recurrence-free survival (RFS) in NSCLC patients is lacking. What is the RFS following surgery in stage I-III NSCLC patients at different timepoints and what factors are associated with RFS? A systematic search was performed in MEDLINE, EMBASE and Cochrane databases between January 2011-June 2021. The primary outcome was RFS at 1-, 2-, 3-, and 5-years post-resection. Single-arm, random-effects meta-analyses calculated effect estimates and 95% confidence intervals (CI). Analyses were stratified by stage/sub-stage per the American Joint Committee on Cancer Staging Manual, and RFS was estimated 1) after pooling studies using 7th or 8th edition staging criteria and 2) among studies using only 8th edition. Meta-regressions were performed to assess associations between RFS and patient demographic/clinical characteristics of interest. Data from 471 studies comprising 1,060 surgical study arms were extracted. RFS estimates from 60,695 patients staged with 7th or 8th edition were analyzed. RFS ranged from 96% at 1-year post-resection to 82% at 5 years for stage I, and from 68% at 1-year to 34% at 5 years for stage III. Estimates for patients staged using only 8th edition criteria were slightly higher. Older age, higher percentage of males, advancing stage, larger tumor size, and geographical region (North America/Europe vs. Asia) were significantly associated with worse RFS. This study presents a comprehensive assessment of reported RFS from published clinical literature, offering estimates at multiple post-surgical time points and by geographical region. Findings can inform treatment decisions, clinical trial design, and future research to improve outcomes among NSCLC patients. Protocol was not registered, but study was conducted based on a pre-specified protocol.

1 July 2021 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
RRRavi Rajaram
Ravi Rajaram
DRDavid C. Rice
David C. Rice
YLYanli Li
Yanli Li
EBEduardo Bruera
Eduardo Bruera
ELEmelline Liu
Emelline Liu
DODaniel S. Oh
Daniel S. Oh

1 July 2020 in Clinical Lung Cancer
Verified
Journal Article
Closed access
RRRavi Rajaram
Ravi Rajaram
ACArlene M. Correa
Arlene M. Correa
TXTing Xu
Ting Xu
QNQuynh-Nhu Nguyen
Quynh-Nhu Nguyen
MAMara B. Antonoff
Mara B. Antonoff
BSBoris Sepesi
Boris Sepesi

1 March 2021 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
RRRavi Rajaram
Ravi Rajaram
JAJuan A. Abreu
Juan A. Abreu
RMReza Mehran
Reza Mehran
TNTom C. Nguyen
Tom C. Nguyen
MAMara B. Antonoff
Mara B. Antonoff
AVAra Vaporciyan
Ara Vaporciyan

15 February 2023 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
NZNicolas Zhou
Nicolas Zhou
JNJiangong Niu
Jiangong Niu
DNDavid Nelson
David Nelson
HFHope A. Feldman
Hope A. Feldman
MAMara B. Antonoff
Mara B. Antonoff
RRRavi Rajaram
Ravi Rajaram

26 April 2023 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
NDNathaniel Deboever
Nathaniel Deboever
ACArlene M. Correa
Arlene M. Correa
HFHope Feldman
Hope Feldman
UMUrvashi Mathur
Urvashi Mathur
WHWayne L. Hofstetter
Wayne L. Hofstetter
RRRavi Rajaram
Ravi Rajaram